Background: Following injury to the rotator cuff and anterior cruciate ligament, a direct enthesis is not regenerated, and healing occurs with biomechanically inferior fibrous tissue. Demineralized bone matrix (DBM) is a collagen scaffold that contains growth factors and is a promising biological material for tendon and ligament repair because it can regenerate a direct fibrocartilaginous insertion via endochondral ossification.
Tendon and ligament insert into bone at a specialized site called the enthesis, which allows efficient stress distribution from muscle to bone during joint motion. 2 "Direct" entheses occur at anatomic sites that are subject to high loading and cyclic stress and exhibit a 4-zone gradient in tissue, with varying tissue composition having different mechanical properties. 5 The first zone is tendon, similar to that found in the tendon midsubstance, with a composition of well-aligned collagen I fibers; the second zone is fibrocartilage, with a composition of type II and III collagen; the third zone is calcified fibrocartilage, with a composition predominately of type II collagen; and the fourth zone is bone, characterized by type I collagen and mineral content. 47 The tidemark refers to the mechanical boundary between the calcified and uncalcified fibrocartilaginous zones, and it is important for reducing damage to soft tissues during joint movement. 1 The anterior cruciate ligament (ACL) and rotator cuff insertion are examples of direct entheses that develop via endochondral ossification. 46 "Indirect" entheses are typically found at metaphyseal insertions and are characterized by dense fibrous tissue that attaches to bone indirectly through the periosteum. 4 Direct entheses are susceptible to overuse injuries and trauma. 4 Following injury, the body is unable to regenerate a direct-type fibrocartilaginous enthesis but instead forms an indirect-type enthesis with inferior biomechanical properties that can lead potentially damaging stress concentrations. 8, 17, 42 In the context of rotator cuff injuries following tendon repair, studies have shown that the defect is replaced by biomechanically inferior fibrovascular tissue, 8, 17, 26, 41, 44 and high rates of rerupture have been reported. 16 When associated with osteopenia of the greater tuberosity, this appears to be associated with compromised suture anchorage for operative repair and reduced pullout strength. 7, 50 Similarly, following ACL reconstruction (ACLR), the graft heals by fibrovascular scar tissue at the graft-tunnel interface, 24, 39 which might contribute rerupture rates of up to 6% at 10-year followup. 11 Augmentation of healing at damaged insertion sites remains a surgical challenge for orthopaedic surgeons, and research investigating biological methods to enhance tendon-bone healing is ongoing. 15, 28 Demineralized bone matrix (DBM) is an osteoinductive agent that consists of a collagen scaffold containing several growth factors, such as bone morphogenetic proteins (BMPs), insulin growth factor, transforming growth factor, and fibroblast growth factor. 48 The manufacture of DBM was first described by Urist, 48 and it involves acid extraction of mineral component from bone tissue. 13 Urist described how the implantation of DBM into a soft tissue site led to the formation of bone through endochondral ossification, and this article led to the discovery of BMPs. Allogenic DBM poses minimal risk of foreignbody immunogenic reaction and is in current use clinically for treating bone defects in cases of nonunion. 56 The promise behind DBM for tendon-bone healing in tendon and ligament injuries is that it can induce new bone formation via endochondral ossification 38 and produce a direct-type fibrocartilaginous insertion similar to the native enthesis. 43 In the context of rotator cuff and ACL injuries, the hope is that DBM will promote differentiation of the newly formed tendon-bone junction into a direct-type insertion instead of fibrovascular tissue, which could provide physiological distribution of tensile forces onto the bone insertion site and improve surgical outcomes.
The purpose of this systematic review was to (1) critique preclinical and clinical evidence regarding the use of DBM to biologically augment tendon-bone healing; (2) provide a descriptive summary of the current evidence for DBM use in tendon repair and ACLR, as this is the first systematic review on the topic; and (3) highlight areas of future research to facilitate clinical translation.
METHODS
This systematic review was conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. This review included original peer-reviewed studies based on the following criteria: (1) publication in an English-language journal and (2) an in vivo animal study or clinical study that evaluated the use of DBM in the treatment of tendon repair or ACLR. Studies evaluating biological interventions with recombinant pharmaceutical agents (eg, BMPs in bone defects, spinal injuries, and meniscal injuries) were excluded because the purpose of this review was to focus on DBM applications for tendon-bone healing. Studies reporting in vitro work without in vivo analysis were excluded. Only original peer-reviewed articles were included, so letters, editorials, and review articles were excluded.
The search engines used to identify studies were MED-LINE and EMBASE. The following search terms were used for the literature search: ("demineralized/demineralised bone matrix" OR "demineralized/demineralised cortical bone") AND ("tissue scaffold" OR "tissue engineering" OR "ligament" OR "tendon" OR "anterior cruciate ligament" OR "rotator cuff"). Searches were performed on February 10, 2017, with no date limit applied.
Studies were first screened to assess suitability for inclusion according to the criteria. Then, full article review was performed by 2 authors (A.T.H. and G.B.) to extract the following information: details of the animal model, the groups investigated, the methods of evaluation, and the main findings. Assessment of the study methodological quality was undertaken by 2 authors (A.T.H. and G.B.) using criteria modified from those proposed by Hooijmans et al, 18 as shown in Table 1 . The clinical relevance of outcome measures used in animal studies was scored with a peer-reviewed system 15 as follows: A, clinically useful quantitative outcome measures (eg, anterior-posterior knee laxity); B, biomechanical testing (eg, ultimate tensile strength of the graft); C, quantitative biochemical outcomes (eg, immunohistochemistry); D, semiquantitative histological analysis; and E, simple nonquantitative histological analysis. Interrater reliability was calculated with intraclass correlation coefficient mean measures (SPSS Statistics, v 22; IBM). Figure 1 outlines the process for evaluating studies for inclusion in the systematic review. A total of 339 articles were identified through our search literature search. After removal of duplicates and screening to exclude irrelevant studies, 16 studies underwent full review. Of these, 3 were excluded because they were not written in English, 2 because they were conference papers, and 3 because they were related to tissue engineering of cartilage defects. 31, 34, 53 Eight articles met inclusion criteria: the characteristics of the 4 studies 14, [43] [44] [45] that evaluated tendon injuries are shown in Table 2 , and the characteristics of the 4 studies 19, 20, 22, 27 that evaluated ACLR are shown in Table 3 . No clinical studies were identified, and all 8 studies were preclinical animal studies. The median length of follow-up was 12 weeks (used in 4 studies) and ranged from 6 weeks to 1 year. Six studies 19, 22, 27, 43, 44, 45 evaluated DBM in paste form, and 2 studies 14, 20 evaluated DBM in the form of demineralized cortical bone (DCB). Five studies 14, 20, 22, 43, 44 evaluated allogenic DBM, and 2 studies 19, 27 evaluated xenogenic DBM, with 1 study 45 comparing the 2 forms directly. One study 45 evaluated a combination of biological interventions, which combined mesenchymal stem cells with DBM.
RESULTS

Search Results
Assessment of Methodological Quality
The scores for methodological quality (out of 8) for all studies were as follows: 5 for 2 studies, 6 for 2 studies, 7 for 2 studies, and 8 for 2 studies. Acceptable interrater reliability was seen between the 2 reviewers (intraclass correlation coefficient mean measures, 0.792). Consensus on final scores was reached following mutual discussion, with the majority of differences between reviewers seen in their evaluation of the robustness of the statistical analysis used in the studies. Studies lost points for not performing biomechanical testing (n ¼ 5), conducting bilateral operations in 1 animal (n ¼ 2), and not having an appropriate control group/statistics (n ¼ 4).
In terms of outcome measures, 4 studies ranked A, 1 study ranked B, 1 study ranked C, and 2 studies ranked D. All studies used histological outcomes, with quantitative histological analysis performed in 6 studies. 19, 22, 27, 43, 44, 45 Immunohistochemistry was utilized in 2 studies, 19, 27 with both measuring BMPs and vascular endothelial growth factor. Biomechanical testing was performed in 3 studies, 20, 27, 43 consisting of various tensile failure tests. Peripheral quantitative computed tomography was used in 4 studies 14, 27, 44, 45 to assess bone formation at the grafttunnel interface. Four studies 14, 20, 43, 45 evaluated quantitative outcome measures analogous to clinical outcome measures, such as gait analysis and knee laxity.
Appraisal of Study Outcomes
In this systematic review, we defined a positive finding as a study where the use of DBM augmentation provided superior results in terms of histological scores as compared with a nonaugmented control group. Out of the 8 studies, 5 19, 22, 27, 43, 44 compared DBM with a nonaugmented control group. Of these 5, 4 19, 22, 27, 43 demonstrated positive results for DBM augmentation, and 1 44 observed no difference. Of the 3 studies with no nonaugmented control, 1 45 compared 2 types of DBM (allogenic and xenogenic) and showed that allogenic DBM was superior in terms of histological and gait analysis. The other 2 studies 14, 20 reported favorable findings of DBM-augmented constructs in terms of histological, biomechanical, and radiological outcomes but did not compare their findings with a control group.
DISCUSSION
DBM is an osteoinductive scaffold that has potential in augmentation of tendon-bone healing. This systematic review found that the level of evidence pertaining to the use of DBM in tendon-bone healing is low and remains at the preclinical stage. In this section, we appraise the existing 8 animal studies, critique the representativeness of animal models, and highlight areas for future research if clinical translation is to be achieved.
DBM in Tendon Repair
Four studies evaluating DBM in tendon repair were reported, all of which were from the same laboratory, consisting of 3 studies with a sheep animal model and 1 with a rodent animal model. The first study to evaluate the use of DBM at a healing enthesis was based on an ovine patellar tendon model, 43 which allows functional recovery to be directly evaluated because the entire extensor mechanism depends on the tendon-bone interface. Ovine patellar tendon was detached from its insertion on the tibia and repaired with suture anchors alone (control group) or with allogenic DBM interposed between the tendon and bone (intervention group). After 12 weeks, the DBM group demonstrated better functional weightbearing than the controls and with no failures, compared with 33% failure in the control group. Histologically, the control group demonstrated a largely fibrous insertion, whereas in the DBM group, the tendon-bone interface had remodeled into an organized fibrocartilaginous insertion with mineralization. Elnikety et al 14 reported that DBM successfully repaired "large tendon" defects in their work, where allogenic DBM in the form of a strip (ie, DCB) was used to replace a large patellar tendon defect in 6 sheep. After 12 weeks, there was evidence of mature remodeling with the formation of a neoenthesis composed of fibrocartilage and mineralized fibrocartilage. Polarized microscopy confirmed that the haversian system arrangement of the bone was lost and that the collagen had remodeled into a longitudinal arrangement, indicating the process of "ligamentization." 35 The only study identified in this systematic review with a negative finding used a chronic rotator cuff tear model in rats. 44 In this study, when compared with nonaugmented repair and augmented repair with commercially available dermal matrix, allogenic DBM was not associated with improved histological remodeling. In all animals, histological analysis showed that the tendon-bone gap closed with a fibrocartilaginous insertion, although the degeneration of the tendon was not reversed. Bone mineral density was measured with peripheral quantitative computed tomography at the humeral head, as this is thought to influence pullout strengths, 7 and nonaugmented repairs had higher bone mineral density than both augmented groups.
Thangarajah et al 45 reported the first and only study to date that utilized a combination of stem cells with DCM to evaluate tendon-bone healing. In this work, a 1-cm transverse patellar tendon defect in an ovine model was repaired with suture anchors and either allogenic or xenogenic DBM combined with minimally manipulated mesenchymal stem cells isolated by centrifugation of iliac crest bone marrow aspiration during surgery. After 12 weeks, a 4-zone direct neoenthesis was observed in both groups, but the allograft DBM group was associated with more mature fibrocartilaginous and higher functional weightbearing scores. The authors attributed the better outcome seen in the allograft group to the fact that ovine bone has a higher density of bone when compared with porcine bone, We define a positive finding as a study where DBM augmentation provided superior histological scores when compared with a nonaugmented control group. 
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thus allowing better tolerance of the mechanical forces and microtrauma across the graft. A limitation of this study is that it did not have a group without minimally manipulated mesenchymal stem cells, which makes the influence of the stem cells on the outcome difficult to determine. ACLR, anterior cruciate ligament reconstruction; AP, anteroposterior; BMP2, bone morphogenetic protein 2; BMP7, bone morphogenetic protein 7; CTSK, cathepsin; DBM, demineralized bone matrix; DCB, demineralized cortical bone; DCM, demineralized cortical bone; MRI, magnetic resonance imaging; n/a, not applicable; pQCT, peripheral quantitative computer topography; SQ, semiquantitative; UTS, ultimate tensile strength; VEGF, vascular endothelial growth factor. We define a positive finding as a study where DBM augmentation provided superior histological scores when compared with a nonaugmented control group. 
DBM in ACL Reconstruction
The longest in vivo follow-up of the use of DBM in ACL-bone healing was in 1996 when Jackson et al 20 used allogenic DBM in DCB form in a goat animal model of ACLR. DCB strips were trimmed to fit through a femoral and tibial tunnel to reconstruct the ACL. Histological analysis showed replacement of DCB with bone within the osseous tunnels and the presence of a more physiological fibrocartilage transition at the graft insertion site. Magnetic resonance image scans showed that the osseous tunnels were nearly obliterated with a signal similar to bone. There was a 550% increase in graft strength at 1 year, although the ultimate tensile strength was statistically significantly less than control ACLs.
Kilicoglu et al 22 evaluated the effect of allogenic DBM within a tibial osseous tunnel in a rabbit model of ACL injury and in the first 6 weeks observed slightly increased fibrocartilage formation and more bone formation in the DBM group than the nonaugmented control. However, the superiority was short-term, and by 9 weeks, there were no differences in histology, with both groups showing replacement of fibrocartilage with calcified cartilage and new bone. Conversely, Hsu and Wang 19 found that rabbits that had xenogenic (human) DBM applied to the tibial tunnel showed superiority versus nonaugmented repair at 12 weeks. Histological examination showed more intimate contact between tendon and bone in the DBM group with more mineralized fibrocartilage between tendon and bone, which corresponded to higher levels of expression of BMP-2 and vascular endothelial growth factor.
Lovric et al 27 performed a study with a rodent model where the intervention group had xenogenic (human) DBM inserted into the femoral and tibial bone tunnels before reconstruction. When compared with a control group, the DBM group had considerably more woven bone formation at the interface, as confirmed on histology and micro-computed tomography, which was associated with statistically higher levels of peak load to failure of the tendon-bone interface. Immunohistochemistry revealed higher levels of BMPs throughout, such as BMP-2 and BMP-7, which were thought to be responsible for the higher level of new bone formation.
Representativeness of Animal Models
Animal models are a useful way to investigate interventions and to see if it is worthwhile to take them into human clinical trials. 9 Requirements of animal models in translational orthopaedic research into tendon-bone healing include the following: the model must be comparable to the human environment; the surgery must be feasible, affordable, and ethically acceptable; and animals need to be able to tolerate the rehabilitation and have suitable facilities available. 30 A range of small-animal models (rodents, rabbits) 19, 22, 27, 44 and large-animal models (goats, sheep) 20, 43, 45 has been used to evaluate the effect of DBM on tendon-bone healing; nevertheless, they are not without limitations. Considerable anatomic differences exist between animals and humans, especially in terms of gait and posture, which can lead to different biomechanical stresses. 37 The use of rodent animal models makes the interpretation of results for humans difficult. Rodent models seem to produce significant amounts of fibrous tissue that are not seen in humans, and the pathology associated with tendon damage is different from humans. 6 The limited surface area in rodent models might not create an environment conducive to healing owing to high shear forces, which brings into question the suitability of rodent models for assessing tendon-bone healing 44 and might account for the rodent animal model being unable to reproduce promising results seen with DBM in the large-animal models. Further doubt over the suitability of rodent models of rotator cuff pathology is that spontaneous bone healing of the humerus occurs, which is not thought to happen in humans. 44 There have been 3 large-animal studies (ovine) investigating tendon injury, but the use of DBM for ACLR has been investigated in only 1 large-animal model (goat). There have been 3 large-animal studies (ovine) investigating tendon injury, but the use of DBM for ACLR has been investigated in only 1 large-animal model (goat). A limitation of the studies using large-animal models is that they have used a relatively low number of animals with no reported power calculation. Reasons why studies using small animals generally evaluate larger numbers of animals include small animals (eg, rabbits) having simpler requirements for animal maintenance and housing when compared with larger animals, as well as their potential for faster postoperative recovery.
3 Dogs 33,40 and pigs 10, 23 are recognized large-animal models of ACLR that have not been used to evaluate DBM modulation of ACLR, despite some evidence that pigs best reflect human knee in situ forces. 55 In the context of tendon injuries, large-animal models have only simulated acute injuries, with the only chronic model of disease being a study in rodents. Acute injury models are useful when investigating the formation of the enthesis, but they do not consider the condition of the tendon, which, in human clinical situations at the time of surgery, is retracted with fatty infiltration. 9, 17 Similarly, in models of ACLR, the creation of the injury and the surgical reconstruction have always occurred in the same operation, which does not reflect the delay seen in human patients between injury and surgery owing to the preoperative workup. This might have implications because during acute injury there is a release of cytokines and a change in gene expression, which might create a biological environment different from that seen in human patients undergoing ACLR. 49, 54 The published animals models reported here are also relatively short term, and in this analysis, most of the studies were conducted for <6 months. While this length of time may be appropriate for investigating bone-graft integration, remodeling and ligamentization may take longer. In addition, the surgical procedures for the ACL animal models have all been open, which does not reflect the current surgical practice of arthroscopic reconstruction.
Steps Toward Clinical Translation
This systematic review aimed to review preclinical and clinical evidence behind the use of DBM to augment tendon-bone healing. There were no clinical studies identified, which means that general statements about the effectiveness of DBM to augment tendon-bone healing cannot be made.
More preclinical data are required to justify the use of DBM in clinical trials, and the following areas need to be addressed in particular. First, the best source and method of manufacturing DBM for clinical applications need to be determined, 12 reflected by the fact that the strength and biological activity of DBM that is currently available are variable. The biological activity of bone obtained from a young donor compared with that from an older individual would be different; therefore, there is not a consistent supply of DCB. Xenogeneic DCB might be advantageous, as the biological activity of the graft material would be reproducible and there would be an unlimited supply of graft material, although there might be problems with immunogenic activity. Thangarajah et al 45 showed that allograft has superior results to xenograft in tendon-bone healing, but further studies comparing xenograft and allograft, with long-term follow-up assessing for immunological reactions, are needed before DBM can be used in humans.
Second, DBM can be created in the form of DCB, 44 although this is not commercially available at present. Theoretically, instead of being used to augment tendon reconstruction, the DCB could be used as the primary graft material for reconstruction, with the promise of forming a tendon enthesis via endochondral ossification. Future large-animal studies of ACLR are required that compare DCB reconstruction with DBM augmentation, but these need to have follow-up for at least 6 months to provide time for ligamentization to occur. 35 In addition, longer-term studies are needed to clarify if the benefit of DBM is just in the first 3 weeks, as suggested by 1 study, 22 or longer lasting, as suggested by others. 19, 43, 45 Finally, as tendon healing involves different stages, such as inflammation, vascularization, and remodeling, it might be possible to enhance tendon-bone healing by using a combination of biological interventions. Future animal studies that combine DBM with other biological approaches to augment tendon-bone healing merit investigation, such as tissue scaffolds, 25, 36, 57 gene therapy, 21, 29, 32 and biophysical interventions. 51, 52 Before biological interventions achieve clinical translation in addition to demonstrating safety profile and clinical efficacy, they will need to be cost-effective given the current environment of cost containment.
CONCLUSION
The enthesis has a complex composition, structure, and mechanical behavior that effectively transfer stress from tendon to bone. Injuries to the rotator cuff and ACL are common sports injuries that have high rates of early failure, which is thought to be due in part to inadequate healing at the tendon-bone interface. DBM is a promising biomaterial because it provides a protein scaffold with its own supply of growth factors capable of repairing small/ large tendon defects and it augments ACLR by creating a 4-zone fibrocartilaginous enthesis and enhancing osseointegration. DBM shows promise in animal studies, but the use of DBM in tendon-bone healing remains in the exploratory stage with no clinical research undertaken. Future research is required to determine the best source (allogenic versus xenogenic) and best form (augmentation versus reconstruction) of DBM to take forward into clinical trials.
